PE68799A1 - Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina - Google Patents

Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina

Info

Publication number
PE68799A1
PE68799A1 PE1998000326A PE00032698A PE68799A1 PE 68799 A1 PE68799 A1 PE 68799A1 PE 1998000326 A PE1998000326 A PE 1998000326A PE 00032698 A PE00032698 A PE 00032698A PE 68799 A1 PE68799 A1 PE 68799A1
Authority
PE
Peru
Prior art keywords
dopamine
compound
carboxamide
alkyl
refers
Prior art date
Application number
PE1998000326A
Other languages
English (en)
Inventor
Clive Leslie Branch
Christopher Norbert Johnson
Geoffrey Stemp
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9708976.7A external-priority patent/GB9708976D0/en
Priority claimed from GBGB9723294.6A external-priority patent/GB9723294D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE68799A1 publication Critical patent/PE68799A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) Y SUS SALES; DONDE, R1 ES H, HALOGENO, HIDROXI, R3R4NSO2(CH2)p, ENTRE OTROS; R3 Y R4 SON INDEPENDIENTEMENTE H O ALQUILO C1-C4, UN ANILLO AZACICLOALCANO C3-C6, ENTRE OTROS; p ES CERO-4; R2 ES H O ALQUILO C1-C4; q ES 1 o 2; "A" ES -Ar, -Ar1-Y-Ar2, -CH=CH-Ar; Ar ES FENILO, HETEROCICLO DE 5-6 MIEMBROS, ANILLO BICICLICO OPCIONALMENTE SUSTITUIDO; Ar1 Y Ar2 SON FENILO, ANILLO AROMATICO HETEROCICLICO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO; "Y" ES UN ENLACE, -NHCO-, -CONH-, -CH2-, ENTRE OTROS; CUANDO "A" ES -Ar, UN SUSTITUYENTE EN POSICION ORTO RESPECTO AL RESTO CARBOXAMIDA ES H o METOXI. UN COMPUESTO PREFERIDO ES TRANS-6-CIANO-2-(2-(1-(4-(4-QUINOLINIL)CARBOXAMIDO)CICLOHEXIL)ETIL)-1,2,3,4-TETRAHIDROISOQUINOLEINA Y LA SAL MONOHIDROCLORURO O MONOMESILATO, ENTRE OTROS. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION. EL COMPUESTO DE FORMULA (I) MODULA EL RECEPTOR DOPAMINA D3 ACTUANDO COMO AGONISTA, PUDIENDO SER UTIL EN EL TRATAMIENTO DE CONDICION PSICOTICA COMO LA ESQUIZOFRENIA
PE1998000326A 1997-05-03 1998-04-29 Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina PE68799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9708976.7A GB9708976D0 (en) 1997-05-03 1997-05-03 Compounds
GBGB9723294.6A GB9723294D0 (en) 1997-11-04 1997-11-04 Compounds

Publications (1)

Publication Number Publication Date
PE68799A1 true PE68799A1 (es) 1999-09-26

Family

ID=26311476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000326A PE68799A1 (es) 1997-05-03 1998-04-29 Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina

Country Status (17)

Country Link
US (1) US6465485B1 (es)
EP (1) EP0983244A1 (es)
JP (1) JP2002501506A (es)
CN (1) CN1261350A (es)
AR (1) AR013078A1 (es)
AU (1) AU725491B2 (es)
BR (1) BR9809591A (es)
CA (1) CA2288899A1 (es)
HU (1) HUP0003608A3 (es)
IL (1) IL132631A0 (es)
MA (1) MA26490A1 (es)
NO (1) NO995338L (es)
PE (1) PE68799A1 (es)
PL (1) PL336628A1 (es)
TR (1) TR199902724T2 (es)
UY (1) UY24986A1 (es)
WO (1) WO1998050364A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
CA2311131A1 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
US6429207B1 (en) * 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
GB9810876D0 (en) * 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
GB9812522D0 (en) * 1998-06-10 1998-08-05 Smithkline Beecham Plc Compounds
US6855717B2 (en) * 1998-06-10 2005-02-15 Smithkline Beecham, Plc Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
EA200100428A1 (ru) 1998-10-08 2001-10-22 Смитклайн Бичам Плс Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
GB9821978D0 (en) * 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
GB9821977D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
AR022229A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
AU2003218660A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
KR20080064953A (ko) * 2005-10-13 2008-07-10 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 항균 활성을 갖는 5-퀴놀린 유도체
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
JP5701213B2 (ja) 2008-10-10 2015-04-15 インスティチュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ 新規なドーパミンd3受容体リガンド、その調製及び使用
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
EP2791139B1 (en) * 2011-12-12 2017-11-08 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
MX2018014032A (es) 2017-03-20 2019-08-21 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
JPWO2019146739A1 (ja) * 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する縮環化合物
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220778A (en) * 1978-10-30 1980-09-02 G. D. Searle & Co. 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
FR2706895A1 (en) * 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
IL126747A0 (en) * 1996-05-11 1999-08-17 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
WO1998006699A1 (en) * 1996-08-14 1998-02-19 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
PL336628A1 (en) 2000-07-03
AU7651898A (en) 1998-11-27
NO995338D0 (no) 1999-11-02
CN1261350A (zh) 2000-07-26
IL132631A0 (en) 2001-03-19
EP0983244A1 (en) 2000-03-08
BR9809591A (pt) 2001-09-11
AR013078A1 (es) 2000-12-13
TR199902724T2 (xx) 2000-04-21
JP2002501506A (ja) 2002-01-15
UY24986A1 (es) 2001-08-27
CA2288899A1 (en) 1998-11-12
AU725491B2 (en) 2000-10-12
NO995338L (no) 1999-11-02
US6465485B1 (en) 2002-10-15
WO1998050364A1 (en) 1998-11-12
HUP0003608A2 (en) 2001-03-28
HUP0003608A3 (en) 2001-06-28
MA26490A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PE68799A1 (es) Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
NO20032161L (no) Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamine D3-reseptor (antipsykotiske midler)
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20000728A1 (es) Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
PE20010759A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20031011A1 (es) Derivados de dihidrobenzodiazepin-2-ona-iii
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE97799A1 (es) Derivados de piridina
EE200200079A (et) Heteropolütsüklilised ühendid ja nende kasutaminemetabotroopsete glutamaadiretseptorite antagonistidena
PT87183A (pt) Procede de preparation de derives d:aryl-heteroaryl carbinol avec activite analgesique
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
UA81561C2 (en) Use of n-arylhydrazine derivative and method for controlling non-crop pests
DE69819266D1 (de) Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
PE20081495A1 (es) Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.
ATE187448T1 (de) Morpholinderivate
MEP17408A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
DE69805831T2 (de) 1,4-disubstituierte cyclohexan-derivate als liganden der 5ht1a rezeptoren
ES2072193B1 (es) Nuevos derivados del1-fenilmetil bencimidazol piperacinas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed